| Literature DB >> 34163210 |
Magdalena Pawelczyk-Madalińska1,2,3, Reem Hanna1,4, Stefano Benedicenti1, Tudor Sălăgean5, Ioana Roxana Bordea6.
Abstract
BACKGROUND: Due to the limitations of scaling and root planing (SRP) in chronic periodontitis (CP) management, research has been focused on utilising additional therapies to enhance conventional treatment methods. The present systematic review is aimed to appraise the accessible scientific evidence of in vivo human studies to establish the effectiveness of adjunctive diode (λ 808- λ 980nm) laser treatment to SRP in CP.Entities:
Keywords: RCTs; chronic periodontitis; diodes laser treatment; high intensity laser; non-surgical periodontal therapy; randomised controlled trials studies; scaling and root planing; systematic diseases
Year: 2021 PMID: 34163210 PMCID: PMC8214554 DOI: 10.2147/JIR.S304946
Source DB: PubMed Journal: J Inflamm Res ISSN: 1178-7031
Figure 1PRISMA flow-chart of the study selection criteria for the included article reports.
Notes: Adapted from Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. © 2009 Moher et al. Creative Commons Attribution License.39
Shows a Tabular Representation of All the Eligible Randomized Controlled Trials Studies in Terms of Demography, Study Design, Journal Published in Peer Reviewed Journal, Industry Funds, Ethical Approval, Intervention Groups, Number of Laser Session After SRP Influencing Factors (Systemic Diseases and Smoking), Treatment Duration and Percentage of Documentation
| Author and Citation | Origin of the Paper | Systematic Disease | Smoker | Laser Treatment Session (Day) After SRP | Type of Study | Published in a Peer Reviewed Journal | Ethical Approval | No. of Participants | M/F | Age (Range/Mean) ± SD) | Age of SPR/SPR + Laser Groups | No. of Pocket | Saline Irrigation After Lasing | Duration of Treatment (Days) | PD ≥4 mm/≥5mm |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chandra et al 2019 | INDIA | NIDDM | No | 0 | Parallel | No | Yes | 3 | 18/18 | 30–60 | 50.6/48.05 | – | No | 90 | Yes/yes |
| Euzebio Alves et al 2013 | BRAZIL | No | No | 0,7th | Split mouth | Yes | Yes | 46 | 13/23 | 37–64/46±8.11 | – | – | No | 180 | -/Yes |
| De Micheli et al 2011 | BRAZIL | No | No | 0,7th | Split mouth | Yes | Yes | 27 | 8/19 | -/48.5 | - | - | No | 42 | -/Yes |
| Meseli et al 2019 | Turkey | No | No | 0 | Split mouth | No | Yes | 11 | - | 35–65/44.09± 4.48 | - | 56 | No | 133 | -/Yes |
| Dengizek et al 2018 | TURKEY | NIDDM | No | 0 | Parallel | Yes | Yes | 37 | 17/20 | 43–57 | 49.7±6.63/5.85±6.23 | - | No | 180 | Yes/yes |
| Dakhil et al 2019 | IRAQ | NIDDM | - | 0,7th,14th | Split mouth | No | - | 20 | - | 35–65 | - | - | No | 90 | Yes/- |
| Nguyen et al 2015 | USA | No | Yes | 0 | Split mouth | Yes | Yes | 22 | 13/9 | 47–81/61.8 | - | 56+58 | No | 90 | -/yes |
| Saglam et al 2014 | TURKEY | No | No | 0 | Parallel | Yes | Yes | 30 | 18/12 | 32–57 | 40.83±7.64/42.13±9.05 | - | Yes | 180 | -/yes |
| Kocak et al 2016 | TURKEY | NIDDM | No | 0 | Parallel | Yes | Yes | 60 | 30/30 | 35–60 | 53.1/51.7 | - | No | 90 | -/yes |
| Hatipoglu et al 2017 | TURKEY | No | No | 0 | Parallel | No | Yes | 40 | 20/20 | - | - | - | No | 180 | -/yes |
| Crispino et al 2015 | ITALY | No | Yes | 0 | Split mouth | No | - | 68 | - | -/56.3 | - | 1224 | No | 120 | Yes/yes |
| Balasubramaniam et al 2014 | INDIA | No | No | 0 | Parallel | Yes | Yes | 30 | 18/12 | 18–65/38–27±14.1 | - | 1650 | No | 60 | Yes/- |
| Dukic et al 2013 | CROATIA | No | No | 0,3rd,7th | Split mouth | Yes | Yes | 35 | 21/14 | 26–48/37±10.8 | - | 474+451 | No | 126 | Yes/- |
| Zare et al 2014 | IRAN | Systemic diseases excluding bleeding disorders | No | 0 | Split mouth | No | - | 21 | 11/10 | -/42.2 | - | 207 | No | 600 | Yes/- |
| Yadwad et al 2017 | INDIA | No | No | 7th,14th | Parallel | Yes | - | 40 | - | 30–50 | - | - | No | 84–98 | -/yes |
| 100% | 100% | 93,33% | 100% | 100% | 100% | 73.33% | 100% | 73,33% | 93,33% | 73,33% | 40% | 100% | 100% | 100% |
Abbreviations: NIDDM, non-insulin depended diabetes mellitus; SPR, scaling and root planning; SPR + laser, scaling and root planning and laser; F, female; M, male; No., number; SD, standard deviation.
Figure 2Illustrates the percentage of the gender distribution according to the number of the recruited subjects.
Shows a Tabular Representation of Diode Laser-Assisted Treatment Parameters Reported in the Included Eligible Randomized Controlled Trials Studies
| Author and Citation | Wavelength (nm) | Power Output (Watt) | Peak Power (Watt) | Average Power (Watt) | Fluence (J/cm2), J/mm2 | Emission Mode | Tip Movement | Pulse Frequency (Hz) | Duty Cycle (Time on/Time off) (msec) | Irradiance W/cm2 | Time Treatment for Pocket (sec) | Spot Size (mm) μ | Power Meter | Hot Tip (Initiation) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chandra et al, 2019 | 808 | 1.5–1.8 | – | – | – | CW | – | – | – | – | – | 320 | – | – |
| Euzebio Alves et al, 2013 | 808 | 1.5 | – | – | – | CW | – | – | – | 1193 | 40 | 400 | Yes | – |
| De Micheli et al, 2011 | 808 | 1.5 | – | – | – | CW | – | – | – | 1193 | 40 | 400 | Yes | – |
| Meseli et al, 2019 | 810 | 1 | – | – | – | CW | – | – | – | – | 20 | 200 | – | – |
| Dengizek et al, 2018 | 810 | 1 | – | – | – | Gated | – | – | – | – | 45/60 | 400 | – | – |
| Dakhil et al, 2019 | 940 | 0.8 | – | – | – | CW | – | – | – | – | 20 | 300 | – | – |
| Nguyen et al, 2015 | 940 | 0.8 | – | – | 0.8 | CW | – | – | – | – | – | – | – | Yes |
| Saglam et al, 2014 | 940 | 1.5 | – | – | 15 | Gated | – | – | 20/20 | – | 20 | 300 | – | – |
| Kocak et al, 2016 | 940 | – | – | 1.5 | 15/20 respectively | Gated | – | – | 20/20 | – | 20 | 300 | – | – |
| Hatipoğlu et al, 2017 | 940 | 1.5 | – | – | 15 | Gated | – | – | 20/20 | – | 20 | 300 | – | – |
| Crispino et al, 2015 | 940 | 3 | 3 | 1 | 1.2 J/mm | Pulsed | – | 15 | 10/20 | – | – | 300–400 | – | Yes |
| Balasubbramani et al, 2014 | 970±15 | 1 | – | – | 93.4 | CW | – | – | – | 2820 | 30x2* | 320 | Yes | Yes |
| Dukić et al, 2013 | 980 | – | 2 | 0.66 | – | Gated | – | – | 25/50 | – | 20 | 300 | – | – |
| Zare et al, 2014 | 980 | 1 | – | – | – | CW | 2 mm/sec | – | – | – | – | 400 | – | – |
| Yadwad et al, 2017 | 980 | 2 | – | – | – | CW | – | – | – | 2487 | 30x2* | 320 | – | – |
Note: Treatment time, 30x2*means 60 seconds interval between lasing (thermal relaxation time).
Abbreviations: (-), unreported; J, joule; W, watt; cm2, square centimetre; Sec, second; mm, millimetre.
Figure 3Illustrates the percentage of various wavelengths utilised in the selected studies and the number between brackets shows the number of the studies in which wavelength used.
Figure 4Shows the percentage of the recruited pocket depth measurements in relation to the utilized wavelengths.
Figure 5Shows the percentage of the missing data related to the laser parameters.
Illustrates the Methods of Assessment for All the Eligible Randomised Controlled Studies, Which Were the Clinical Parameters (PD/PPD, PI, BOP, GI, CAL, GL, API, MGI), Microbiological Analysis (CFU, PCR), Biochemical Markers (CRP, GCF, ROM, HbA1C), as Well the Number of Assessed Variables in Each Study
| Author and Citation | PI | GI | CAL | CFU | HbA1C | PD/PPD | BOP | GCF | CRP | ROM | API | GL | MGI | PCR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chadra et al, 2019 | Yes | Yes | Yes | Yes | Yes | Yes | – | – | – | – | – | – | – | – |
| Alves et al, 2013 | Yes | – | Yes | Yes | – | Yes | Yes | – | – | – | – | – | – | – |
| De Micheli et al, 2011 | Yes | – | Yes | Yes | – | Yes | Yes | – | – | – | – | – | – | – |
| Meseli et al, 2019 | Yes | Yes | – | – | – | Yes | Yes | Yes | – | – | – | – | – | – |
| Dengizek et al, 2018 | Yes | Yes | Yes | – | Yes | Yes | Yes | – | Yes | – | – | – | – | – |
| Dakhil et al, 2019 | – | – | Yes | – | – | Yes | Yes | – | – | – | – | – | – | – |
| Nguyen et al, 2015 | – | – | Yes | – | – | Yes | Yes | Yes | – | – | – | – | – | – |
| Saglam et al, 2014 | Yes | Yes | Yes | – | – | Yes | Yes | Yes | – | – | – | – | – | – |
| Koçak et al, 2016 | Yes | Yes | Yes | – | Yes | Yes | – | Yes | – | – | – | – | – | |
| Hatipoğlu et al, 2017 | Yes | Yes | Yes | – | – | Yes | Yes | – | – | – | – | – | – | – |
| Crispino et al, 2015 | Yes | Yes | – | – | – | Yes | Yes | – | – | – | – | – | – | – |
| Balasubbramani et al, 2014 | Yes | – | Yes | – | – | Yes | Yes | – | – | Yes | – | – | – | – |
| Dukić et al, 2013 | – | – | Yes | – | – | Yes | Yes | – | – | – | Yes | – | – | – |
| Zare et al, 2014 | – | – | – | – | – | Yes | Yes | – | – | – | – | Yes | Yes | – |
| Yadwad et al, 2017 | Yes | Yes | Yes | – | – | Yes | Yes | – | – | – | – | – | – | Yes |
| Number of tests for the selected studies | 11 | 8 | 12 | 3 | 3 | 15 | 13 | 4 | 1 | 1 | 1 | 1 | 1 | 1 |
Abbreviations: PD/PPD, pocket depth/periodontal pocket depth; PI, xx; BOP, bleeding on probing; GI, gingival index; CAL, clinical attachment level; GL, gingival level; API, approximal plaque index; MGI, marginal gingival index; CFU, colony forming units; PCR, polymerase chain reaction; CRP, C-reactive protein; GCF, gingival crevicular fluid; plasma ROM, reactive oxygen metabolite; HbA1C, glycated haemoglobin.
Illustrates the Outcomes and the Follow-Up Period of the Eligible Studies
| Citation | Follow-Up | Outcomes of Treatment |
|---|---|---|
| Chandra et al, 2019 | 3 months | |
| At 3 months: a significant reduction in the CFU (Aa and Pg), but 6.49% more reduction in HbA1c level without statistically significant. | ||
| At 3 months: statistically significant improvement in PI ( | ||
| Euzebio Alves et al, 2013 | 6 weeks | |
| At 6 weeks and 6 months: no statistically significant improvement in CAL, PD, PI and BOP, compared to the control (SRP) | ||
| At 6 weeks: statistically significant reduction in CFU (P>0.05) in Laser +SPR, compared to SRP | ||
| At 6 weeks and 6 months: a statistically significant improvement in the CAL, PD, PI and BOP (P<0.001), | ||
| At 6 months: Reduction in the CFU (Pg, Pi, Aa) was statistically significant in both groups | ||
| De Micheli et al 2011 | 6 weeks | |
| No statistically significant difference in the CAL gain as well in the PPD, | ||
| An increase in the average value of the gingival retraction of 0.6 mm ( | ||
| Statistically significant reduction in the numbers of CFU BT | ||
| Statistically significant in the CAL gain ( | ||
| A reduction in the A.a colonies was higher in the control group, but statistically insignificant ( | ||
| The studied cclinical parameters: the clinical probing depth (CPD) CAL resulted in significant enhancement in the control group, compared to laser group (P = 0.014 and P = 0.039, respectively). The results of the PI and BOP were similar in both groups. | ||
| The microbiological parameters showed no significant differences between both groups. | ||
| Meseli et al, 2019 | 8 weeks | |
| PI, PD, CAL, GI, BOP showed significant improvement; | ||
| GCF volume decreased parallel to the declines in GI and BOP | ||
| Dengizek et al, 2018 | 3,6 months | |
| At 3, 6 months: statistically significant ( | ||
| At 6 months: GI was a statistically significant | ||
| At 3, 6 months: CRP serum and HbA1c levels were similar between the groups ( | ||
| Dakhil et al, 2019 | 3 months | |
| At 3 months: statistically significant gain in the CAL and a reduction in the BOP but no significant differences between the groups | ||
| Nguyen et al, 2015 | 3 months | |
| At 3 months: statistically significant reduction in the PD and BOP and gain in the CAL but not significantly different between groups. | ||
| The GCF IL-1b levels between both groups were not statistically significant. IL-1b levels were not statistically different between both groups (baseline, P <0.36; 3 months, P <0.97). | ||
| Saglam et al, 2014 | 1,3,6 months | |
| Statistically significant ( | ||
| At 1 month: PPD, GI BOP, MMP-8 | ||
| At 3 months: BOP, TIMP-1 | ||
| At 6 months: PI, GI, TIMP-1. The reduction in PD was 1.0 mm and in the gain of CAL was 0.2 mm and both of them | ||
| Koçak et al, 2016 | 1,3 months | |
| At 1, 3 months: statistically significant reduction in the PD of 5 and 6mm and gain in the CAL ( | ||
| At 1, 3 months: the levels of GCF IL-8 showed statistically significant ( | ||
| At 1, 3 months: | ||
| At 3 months: | ||
| Hatipoğlum et al, 2017 | 1,3,6 month | |
| At 1month: significant improvement (p<0.05) in GI level, no significant improvement in PD but significant reduction in the CAL ( | ||
| At 3months: Statistically significant reduction in The PI and GI ( | ||
| At 6 months: Statistically significant improvement in the PI, GI, and BOP ( | ||
| Crispino et al, 2015 | 4 months | |
| The average GI level reduced double compared to the control group (80% vs 44%) | ||
| The PI and PD were reduced by a mean percentage of 67% and 76%, whereas in the control group the mean percentage of reduction was 57% and 58%. | ||
| Balasubramaniam et al, 2014 | 1,2 months | |
| At 1, 2 months: there was no statistically significant in the ROM serum level. Statistically significant improvement in the BOP and CAL gain in single and multirooted teeth | ||
| At 2 months: there was no statistically significant in the clinical parameters. | ||
| At 1, 2 months: statistically significant improvement in the BOP and CAL gain in single and multirooted teeth | ||
| Dukić et al 2013 | 6,18 weeks | |
| At 18 weeks: ONLY statistically significant reduction in the PD of 4–6mm, compared to the baseline (P < 0.05). | ||
| At period time between 6 to 18-week, statistically significant reduction in PD of 4–6mm (P < 0.05). | ||
| At 6, 18 weeks: the results were similar in terms of API, BOP, PD in deep pockets and CAL. | ||
| Zare et al, 2014 | 2 months | |
| Statistically significant improvement in the BOP ( | ||
| Statistically significant reduction in the GL (recession) and MGI ( | ||
| Yadwad et al, 2017 | 4–6weeks | |
| At 4–6 weeks: there was a statistically significant reduction in the Pg level better of 21.2%, compared to the baseline (41,1%). | ||
| At 12–14 weeks: there was no statistically significant increase in Pg level. | ||
| At 4–6 weeks: Statistically significant improvement in the BOP, PI, GI and Pg (PCR) | ||
| At 12–14 weeks: Statistically significant improvement in the BOP, PI, GI, PD and PCR |
Shows the Summary of the Statistical Significance Improvement in the Clinical, Microbiological and Immune-Biochemical Parameters and Markers for SPR Alone Group, SPR + Laser Group, as Well the Difference Between SPR Alone Group and SPR + Laser Group at Various Follow-Up Time-Points
| Follow-Up Time Point | 4–6 Weeks | 2–3 Months | 6 Months | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Author and Citation | Scaling and Root Planning Group | Scaling and Root Planning and Laser Group | Difference Between Scaling and Root Planning and Scaling and Root Planing and Laser Groups | Scaling and Root Planning Group | Scaling and Root Planning and Laser Group | Difference Between Scaling and Root Planning and Scaling and Root Planing and Laser Groups | Scaling and Root Planning Group | Scaling and Root Planning and Laser Group | Difference Between Scaling and Root Planning and Scaling and Root Planing and Laser Groups |
| (SRP) | (SRP + laser) | (SRP alone/SRP+ laser) | (SRP) | (SRP + laser) | (SRP alone/SRP + laser) | (SRP) | (SRP + laser) | (SRP alone/SRP + laser) | |
| Chandra et al, 2019 | CFU, HbA1c, PI, GI, CAL, PD | CFU, HbA1c, PI, GI, CAL, PD | CFU | ||||||
| Euzebio Alves et al, 2013 | CFU, CAL, PD, PI, BOP | CFU, CAL, PD, PI, BOP | 0 | PD, CAL, BOP | PD, CAL, BOP | 0 | |||
| De Micheli et al, 2013 | CAL, GM, PD, CEJ | CAL, GM, PD, CEJ | 0 | CFU, PI, BOP | CFU, PI, BOP | 0 | |||
| Meseli et al, 2019 | CGF, GI, BOP, PD, CAL | CGF, GI, BOP, PD, CAL | 0 | ||||||
| Dengizek et al, 2018 | PI, GI, BOP, PD, HbA1c | PI, GI, BOP, PD, HbA1c | CAL, GI | PI, GI, BOP, PD, HbA1c | PI, GI, BOP, PD, HbA1c | CA, GI | |||
| Dakhil et al, 2019 | CAL, BOP | CAL, BOP | 0 | ||||||
| Nguyen et al, 2015 | PD, BOP, CAL, GCF | PD, BOP, CAL, GCF | 0 | ||||||
| Saglam et al, 2014 | GCF, PD, CAL, BOP | GCF, PD, CAL, BOP | BOP | PD, CAL, GCF, PI, GI, BOP | PD, CAL, GCF, PI, GI, BOP | BOP | PD, CAL, GCF, PI, GI, BOP | PD, CAL, GCF, PI, GI, BOP | PI, GI |
| Kocak et al, 2016 | GCF, PD, CAL, BOP/GI, PI | GCF, PD, CAL, BOP/GI, PI | 0 | PD, CAL, GCF, PI, GI, BOP, HbA1c | PD, CAL, GCF, PI, GI, BOP, HbA1c | 0 | |||
| Hatipoğlu et al, 2017 | PD, CAL, BOP/GI, PI | PD, CAL, BOP/GI, PI | CAL, BOP, PI | PD, CAL, PI, GI, BOP | PD, CAL, PI, GI, BOP | PI | PD, CAL, PI, GI, BOP | PD, CAL, PI, GI, BOP | BOP, PI |
| Crispino et al, 2015 | GI, PI, PD | GI, PI, PD | GI | ||||||
| Balasubbramani et al, 2014 | PD, CAL, BOP/BI, ROM, PI, | PD, CAL, BOP/BI, ROM | 0 | PD, CAL, BOP, ROM | PD, CAL, BOP, ROM | 0 | |||
| Dukić et al, 2013 | PD, CAL, BOP | PD, CAL, BOP | 0 | ||||||
| Zare et al, 2014 | MGI/GI, GL/CAL, BOP | MGI/GI, GL/CAL, BOP | BOP | ||||||
| Yadwad et al, 2017 | GCF, PI, GI, BOP | GCF, PI, GI, BOP | 0 | BOP, CAL, PPD, GI, PI | BOP, CAL, PPD, GI, PI | 0 | |||
Abbreviations: PD/PPD, pocket depth/periodontal pocket depth; PI, plaque index; BOP, bleeding on probing; GI, gingival index; CAL, clinical attachment level; GL, gingival level; API, approximal plaque index; MGI, marginal gingival index; CFU, colony forming units; PCR, polymerase chain reaction; CRP, C-reactive protein; GCF, gingival crevicular fluid; plasma ROM, reactive oxygen metabolite; HbA1C, glycated hemoglobin.
Figure 6Quality assessment of all the included eligible studies (n=15) in 4 domains and overall bias. Studies were graded as low risk (green), moderate risk (some concerns, yellow) or high risk (red) for each domain. There is no summation across fields. The assessment was performed using RoB tool for randomised trials, Version 2.0 (RoB 2).40,41
Figure 7Risk of bias assessment graph of all the included studies expressed as percentages for 4 main domains as well overall bias, based on the agreed answers across two independent authors (MM and RH). The assessment was performed using RoB tool for randomised trials, Version 2.0 (RoB 2).40,41
Figure 8Shows the summary of the risk of Bias assessment of all the domains of the included studies based on agreed answers across two independent authors (MM &RH). The assessment was performed using RoB tool for randomised trials, Version 2.0 (RoB 2).40,41
Figure 9Risk of bias assessment graph of all the included studies for all the domains expressed as percentages, based on agreed answers across two independent authors (MM and RH). The assessment was performed using RoB tool for randomised trials, Version 2.0 (RoB 2).40,41
Figure 10Illustrates the spiral movement of the laser fiber (arrow in yellow) inside the periodontal pocket by which 14 of the selected studies in this systematic review utilized.